Literature DB >> 27393574

Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage.

Grace Chen1, Jungshan Chang1, Dachuan Zhang1, Sandra Pinho1, Jung-Eun Jang1, Paul S Frenette2.   

Abstract

Vaso-occlusive crisis (VOC) is one of the most common complications of sickle cell disease (SCD). Recurrent episodes of VOC may cause irreversible organ damage and early mortality in patients with SCD. Emerging evidence suggests that VOC arises from a complex cascade that involves interactions among multiple blood and endothelial cells in the vasculature. Previous studies have identified αMβ2 integrin (Mac-1) as a critical molecule that mediates heterotypic interactions between red blood cells (RBCs) and adherent leukocytes and promotes VOC in SCD mice. Here, we show that RBC-leukocyte interactions are significantly diminished in Mac-1-deficient SCD mice, leading to an improvement of blood flow rates and prolonged survival time in a tumor necrosis factor-alpha and surgical-trauma-induced VOC model. Mac-1-deletion, however, was not sufficient to reduce SCD-related chronic organ damage. Our results thus suggest uncoupled mechanisms between acute VOC benefits and the long-term complications of SCD that should be considered in future clinical trials.
Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27393574      PMCID: PMC5467695          DOI: 10.1016/j.exphem.2016.06.252

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  31 in total

1.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Knockout-transgenic mouse model of sickle cell disease.

Authors:  T M Ryan; D J Ciavatta; T M Townes
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  Platelet activation in patients with sickle cell disease.

Authors:  T Wun; T Paglieroni; A Rangaswami; P H Franklin; J Welborn; A Cheung; F Tablin
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

4.  Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.

Authors:  Grace Chen; Dachuan Zhang; Tobias A Fuchs; Deepa Manwani; Denisa D Wagner; Paul S Frenette
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

5.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

6.  Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase.

Authors:  F A Wagener; A Eggert; O C Boerman; W J Oyen; A Verhofstad; N G Abraham; G Adema; Y van Kooyk; T de Witte; C G Figdor
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease.

Authors:  T R Kinney; L A Sleeper; W C Wang; R A Zimmerman; C H Pegelow; K Ohene-Frempong; D L Wethers; J A Bello; E P Vichinsky; F G Moser; D M Gallagher; M R DeBaun; O S Platt; S T Miller
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

Review 8.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

9.  Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease.

Authors:  Kori L Wallace; Joel Linden
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

Review 10.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

View more
  9 in total

1.  Elimination of the fibrinogen integrin αMβ2-binding motif improves renal pathology in mice with sickle cell anemia.

Authors:  Md Nasimuzzaman; Paritha I Arumugam; Eric S Mullins; Jeanne M James; Katherine VandenHeuvel; Marilou G Narciso; Maureen A Shaw; Sarah McGraw; Bruce J Aronow; Punam Malik
Journal:  Blood Adv       Date:  2019-05-14

2.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

Review 3.  Sickle cell vaso-occlusion: The dialectic between red cells and white cells.

Authors:  Nicola Conran; Stephen H Embury
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

Review 4.  Emerging disease-modifying therapies for sickle cell disease.

Authors:  Marcus A Carden; Jane Little
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

5.  Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.

Authors:  Elisabetta Lombardi; Alessandro Matte; Antonio M Risitano; Daniel Ricklin; John D Lambris; Denise De Zanet; Sakari T Jokiranta; Nicola Martinelli; Cinzia Scambi; Gianluca Salvagno; Zeno Bisoffi; Chiara Colato; Angela Siciliano; Oscar Bortolami; Mario Mazzuccato; Francesco Zorzi; Luigi De Marco; Lucia De Franceschi
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

Review 6.  In utero Therapy for the Treatment of Sickle Cell Disease: Taking Advantage of the Fetal Immune System.

Authors:  Alba Saenz de Villaverde Cortabarria; Laura Makhoul; John Strouboulis; Giovanna Lombardi; Eugene Oteng-Ntim; Panicos Shangaris
Journal:  Front Cell Dev Biol       Date:  2021-01-22

7.  Sickle Cell Anemia Patients Display an Intricate Cellular and Serum Biomarker Network Highlighted by TCD4+CD69+ Lymphocytes, IL-17/MIP-1β, IL-12/VEGF, and IL-10/IP-10 Axis.

Authors:  Nadja Pinto Garcia; Alexander Leonardo S Júnior; Geyse Adriana S Soares; Thainá Cristina C Costa; Alicia Patrine C Dos Santos; Allyson Guimarães Costa; Andréa Monteiro Tarragô; Rejane Nina Martins; Flávia do Carmo Leão Pontes; Emerson Garcia de Almeida; Erich Vinícius de Paula; Olindo Assis Martins-Filho; Adriana Malheiro
Journal:  J Immunol Res       Date:  2020-01-08       Impact factor: 4.818

8.  Nociceptors protect sickle cell disease mice from vaso-occlusive episodes and chronic organ damage.

Authors:  Chunliang Xu; Maria Gulinello; Paul S Frenette
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

9.  Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.

Authors:  Boris Tchernychev; Huihui Li; Sung-Kyun Lee; Xin Gao; Raghunath Ramanarasimhaiah; Guang Liu; Katherine C Hall; Sylvie G Bernier; Juli E Jones; Susanne Feil; Robert Feil; Emmanuel S Buys; Regina M Graul; Paul S Frenette; Jaime L Masferrer
Journal:  Br J Pharmacol       Date:  2021-05-30       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.